
BIOGRAPHICAL SKETCH

| | |
|--|--|
| NAME Dr.Ampica Mangklabruks (Tel: +66-53-946453, Email:amangkla@mail.med.cmu.ac.th) | POSITION TITLE Associated Professor |
|--|--|

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.*)

| INSTITUTION AND LOCATION | DEGREE (if applicable) | YEAR(s) | FIELD OF STUDY |
|--|---|---------|------------------------------|
| - Faculty of Medicine, Chiang Mai University | B.Sc. (Medical Sciences) | 1978 | |
| - Faculty of Medicine, Chiang Mai University | M.D (Hon) • | 1980 | |
| - The Medical Council of Thailand | Thai Board of Internal medicine | 1984 | Internal Medicine |
| - University of Chicago, Chicago, Illinois | Certificate, Fellowship in Endocrinology | 1989 | Endocrinology and Metabolism |
| -The Royal college of physician of Thailand | Sub board in Endocrinology and metabolism | 1994 | Endocrinology and Metabolism |

A. Positions and Honors.**Positions**

- 1980-1981, Internship, Faculty of Medicine, Chiang Mai University.
- 1981-1984, Resident, Department of Internal Medicine, Chiang Mai University.
- 1984-1987, 1990-1992, Instructor, Department of Internal Medicine, Chiang Mai University
- 1987-1989, Clinical and research fellow, Thyroid Study Unit, Section of Endocrinology, The University of Chicago.
- 1992- 2006, Assistant Professor, Department of Internal Medicine, Chiang Mai University.
- 2006-present, Associated Professor, Department of Internal Medicine, Chiang Mai University.
- 2001- present, Deputy director, Research institute for health science, Chiang Mai University.
- 2001-present, Committee, the Endocrine Society of Thailand

Honors/membership

| | |
|---|------------|
| The Endocrine Society of Thailand | since 1987 |
| The Royal College of Physicians of Thailand | since 1992 |

B. Selected peer-reviewed publications (in chronological order). Do not include publications submitted or in preparation. (*Selected only*)

1. Contributors : Diagnostic Methods in Clinical Thyroidology, Hamburger J.I. ed., NewYork. Springer-Verlag, 1989.
2. DeGroot LJ, Mangklabruks A, McCormick M. Comparison of RA 131I treatment protocols for Graves' disease. *J Endocrinol Invest.* 1990 Feb;13(2):111-8.
3. Medeiros- Neto G, Mangklabruks A, Cox N.J., et al . Defective expression of the thyroid peroxidase gene. In: Carayan P, Ruf J. eds. Thyroperoxidase and Thyroid autoimmunity. Montrouge: Libbey Eurotext; 1990;157-163.
4. Mangklabruks A, Billerbeck A.C, Wajchenberg B, et al. Genetic linkage studies of thyroid peroxidase (TPO) gene in families with TPO deficiency. *J. Clin. Endocrinol. Metab.* 1991;72:471-76.
5. Mangklabruks A, Billerbeck AE, Wajchenberg B, Knobel M, Cox NJ, DeGroot LJ, Medeiros-Neto G. Genetic linkage studies of thyroid peroxidase (TPO) gene in families with TPO deficiency. *J Clin Endocrinol Metab.* 1991 Feb;72(2):471-6.
6. Mangklabruks A, Cox N, DeGroot LJ. Genetic factors in autoimmune Thyroid disease analysed by restriction fragment length polymorphisms of candidate genes. *J. Clin. Endocrinol. Metab.* 1991;73:236-244.
7. Yanagawa T, Mangklabruks A, Chang YB, Okamoto Y, Fisfalen ME, Curran PG, DeGroot LJ. Human histocompatibility leukocyte antigen-DQA1*0501 allele associated with genetic susceptibility to Graves' disease in a Caucasian population. *J Clin Endocrinol Metab.* 1993 Jun;76(6):1569-74.
8. Yanagawa T, Mangklabruks A, DeGroot LJ. Strong association between HLA-DQA1*0501 and Graves' disease in a male Caucasian population. *J Clin Endocrinol Metab.* 1994 Jul;79(1):227-9.
9. Mangklabruks A, Aramrattana A., Limpijarnkit L., Taravijitkul P., Preunglampoo S., Aungboonruang., Kanmanee P., Vachiranakorn J., Rajatanavin R. Factor associated with endemic goiter other than iodine deficiency, A study in Mae Hong Son Province, Thailand. *Journal of the Asean Federation of Endocrines Societies.* 2001;19(1/2):30-34.
10. Aramrattana A, Limpijarnkit L, Leelapat P, Sriphrapadang A, Mangklabruks A, Pruenglampoo S, Vachiranakorn J, Rajatanavin R. Difference in goiter rates between two areas in Mae Hong Son Province despite an equally sufficient iodine supply. *J Med Assoc Thai.* 2002 Jul;85(7):831-8.
11. Rerkasem K., Kosachunhanun S., Chongruksut W., Koiam W., Limpijarnkit L., Chimplee K., Mangklabruks A. A hospital-based survey of risk factors for diabetic foot ulceration in Northern Thailand. *Lower extremity wounds.* 2004; 3(4):220-222.
12. Asawasinsopon R, Prapamontol T, Prakobvitayakit O, Vaneesorn Y, Mangklabruks A, Hock B. Plasma levels of DDT and their association with reproductive hormones in adult men from northern Thailand. *Sci Total Environ.* 2006 Feb 15; 355(1-3):98-105. Epub 2005 Jun 17.
13. Asawasinsopon R, Prapamontol T, Prakobvitayakit O, Vaneesorn Y, Mangklabruks A, Hock B. The Association between organochlorine and thyroid hormone levels in cord serum: A study from northern Thailand. *Environ Int.* 2006 May;32(4):554-9.
14. Sundram F, Robinson BG, Kung A, Lim-Abraham MA, Bay NQ, Chuan LK, Chung JH, Huang SM, Hsu LC, Kamaruddin N, Cheah WK, Kim WB, Koong SS, Lin HD, Mangklabruks A, Paz-Pacheco E, Rauff A, Ladenson PW. Well-differentiated epithelial thyroid cancer management in the Asia Pacific region: a report and clinical practice guideline. *Thyroid.* 2006 May;16(5):461-9.
15. Buranakitjaroen P, Mangklabruks A, Leungwattanakij S, Ngaothamatasn W, Malhotra C, Chee C, Mohamed SR, Dato'Johan RM; Thai-Malaysian-Singapore Erectile Dysfunction Study Group (THAMES Group). Efficacy and safety of sildenafil in Asian males with erectile dysfunction and cardiovascular risk. *J Med Assoc Thai.* 2007 Jun;90(6):1100-8.
16. Aupibul L, Puthanakit T, Lee B, Mangklabruks A, Sirisanthana T, Sirisanthana V. Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. *Antivir Ther.* 2007;12(8):1247-54.
17. Rerkasem K, Kosachunhanun N, Tongprasert S, Khwanngern K, Matanasarawoot A, Thongchai C, Chimplee K, Buranapin S, Chaisrisawadisuk S, Mangklabruks A. Reducing lower extremity

amputations due to diabetes: the application of diabetic-foot protocol in Chiang Mai University Hospital. *Int J Low Extrem Wounds*. 2008 Jun;7(2):88-92. Epub 2008 May 14.

18. Sappamrer R, Prapamontol T, Prakobvitayakit O, Vaneesorn Y, Mangklabruks A, Hock B. Placental transfer of DDT in mother-infant pairs from Northern Thailand. *J Environ Sci Health B*. 2008 Aug;43(6):484-9.
19. Lee B, Aurrpibul L, Sirisanthana V, Mangklabruks A, Sirisanthana T, Puthanakit T. Low prevalence of insulin resistance among HIV-infected children receiving nonnucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thailand. *HIV Med*. 2009 Feb; 10(2):72-8. Epub 2008 Nov 10.

C. Ongoing Research Support

1. MK 0431APN066-02 Mangklabruks (PI) Jan 2008 - Dec 2009
MSD (Thailand) Ltd.
A phase III randomized, active-comparator (Pioglitazone) controlled clinical trial to study the efficacy and safety of MK-0431A (A fixed-dose combination tablet of Sitagliptin and Metformin) in patients with type 2 diabetes mellitus
Role: PI
2. MED-07-12-27A-08 Study Kosachunhanun (PI) 01/07/07-31/12/09
Berlin Pharmaceutical, Ltd.
Efficacy and Safety of Original and Generic Pioglitazone in Type 2 Diabetes Mellitus: A Multicenter, Double-blinded, Randomized-controlled
Role: Co Investigator
3. D1690C00005 Phornphutkul (PI) 01/05/08-01/06/10
AstraZeneca (Thailand) Ltd.
A 24-week, international, randomised, double-blind, parallel-group, multi-centre, placebo-controlled phase III study with a 24-week extension period to evaluate the efficacy and safety of Dapagliflozin in combination with Glimepiride (a Sulphonylurea) in subjects with type 2 diabetes who have inadequate glycaemic control on Glimepiride therapy alone
Role: Co Investigator
4. INS-3707, DiabCare Asia 2008Mangklabruks (PI) 19/12/08-31/03/09
Novo Nordisk Pharma (Thailand)Ltd.
A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complication, Psychosocial Aspects of Diabetic Patients in Asia & To Evaluate Perceptions and Practice of Physicians & Patients About Diabetes Management in Asia
Role: PI
5. Prapamontol (PI) 01/6/2005- 31/5/2510
The Thailand Research Fund/ Royal Golden Jubilee PhD Program, on Pesticide Exposure and Health Risk Assessment
Role: Co Investigator

C. Completed Research Support

1. Mangklabruks (PI) 01/10/02 - 30 /09/03
Thai government budget through Chiang Mai University
Effect of Glutinous rice on type 2 diabetes patients in Northern Thailand
Role :PI
2. Mangklabruks (PI) 01/06/02 - 01 /06/03
Aventis Pharma. Co.Ltd.
A multicentre, multinational, randomized, open study to establish the optimal method for initiating and maintaining Lantus® (insulin glargine) therapy based on a comparison of two treatment algorithms to determine optimal metabolic outcomes, safety, and satisfaction in subjects with Type 2 Diabetes Mellitus.
Role :PI
3. Kosachunhanun (PI) 01/05/03-31/01/04
Health Systems Research Institute
Diabetic Registration
Role : Co-Investigator
4. Diabcare-Asia 2003 Mangklabruks (PI) 01/11/03 – 31/01/04
Novo Nordisk Pharma (Thailand) Ltd.
A survey-study on diabetes management, complication and psychosocial aspect of diabetic patients in Asian countries.
Role : PI
5. PAD- RESEARCH Mangklabruks (PI) 01/12/03 – 31/03/04
Thai Otsuka Pharmaceutical Co., Ltd.
Peripheral Arterial Disease-Screening and Evaluation of Diabetic Patients in Asian Regions Characterized by High Risk Factors
Role : PI
6. A 2581111 Kosachunhanun (PI) 01/05/03-31/05/04
Pfizer (Thailand) Limited.
Study number (A Multicenter, Eight- week Treatment, Single-Step Titration, Open- label Study Assessing the Percentage of Dyslipidemic Patients Achieving LDL Cholesterol Target with Atorvastatin Starting Doses of 10 mg, 20 mg, and 40 mg)
Role : Co-Investigator
7. Mangklabruks (PI) 01/10/03 – 21/12/05
Thai government budget through Chiang Mai University
Short-term effects of parboiled glutinous rice consumption on glucose level and other metabolic control in type 2 diabetes.
Role: PI
8. MA 16620 Lumlertgul (PI) Sep 2003 - May 2006
M .Hoffmann-La Roche Ltd.
An open, randomized, multi-centre trial to investigate the effect of anemia correction on cardiac structure and function in patients with early diabetic nephropathy
Role: Co Investigator
9. AMADEO Study Mangklabruks (PI) 23/06/04-23/12/05
Boehringer Ingelheim Pharmaceutical, Inc.
A prospective, randomised, double-blind, double-dummy, forced-titration, multicentre, parallel group, one year treatment trial to compare MICARDIS® (telmisartan) 80 mg versus COZAAR®(losartan) 100 mg, in hypertensive type 2 diabetic patients with overt nephropathy.
Role: PI
10. AVD 100521 Kosachunhanun (PI) 25 /01/05-25/08/07
GlaxoSmithKline Co.,Ltd.

- A Phase III, 18-month, Multicenter, Randomized, Double-Blind, Active Controlled Clinical Trial to Compare Rosiglitazone versus Glipizide on the Progression of Atherosclerosis in Subjects with Type 2 Diabetes Mellitus and Cardiovascular Disease
11. Role: Co Investigator
Kosachunhanun (PI) 25 /01/05- 25/01/06
Novartis (Thailand) Limited.
Thai Acromegaly Registration
12. Role: Co Investigator
Mangklabruks (PI) Aug 2005-Dec 2007
Eli Lilly and company
A Pivotal, Open-Label, Parallel Study to Evaluate the Safety and Efficacy of Human Insulin Inhalation Powder (HIIP) Compared to Injectable Insulin in Patients with Diabetes and COPD or Asthma
13. Role: PI
Mangklabruks (PI) Feb 2006-Jan 2007
Speedel Pharma Ltd
A randomised, double blind, placebo controlled, parallel group study to assess the effect of the endothelin receptor antagonist avosentan on time to doubling of serum creatinine, end stage renal disease or death in patients with type 2 diabetes mellitus and diabetic nephropathy
14. Role: PI
Mangklabruks (PI) Jan 2006-Jul 2007
A prospective, observational registry to evaluate the introduction of first basal insulin in type 2 diabetic patients inadequately controlled by oral antidiabetic agents in Asia
15. Role: PI
INSPIRE ME Mangklabruks (PI) Jul-Sep 2006
Sanofi Aventis
INternational Study of Prediction of Intra-Abdominal adiposity and its RELationships with cardioMetabolic Risk
16. Role: PI
Kosachunhanun (PI) Jan-Jun 2007
Servier(Thailand) Ltd.
Insulin Secretion and Insulin Sensitivity in Asian Type 2 Diabetes
17. Role: PI
Mangklabruks (PI) 01/10/06 - 30 /06/08
Thai government budget through Chiang Mai University
The study of the most effective and sustainable model for reducing glutinous rice consumption in type 2 diabetes